Bahl & Gaynor Inc. Sells 7,081 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Bahl & Gaynor Inc. cut its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 5.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 122,247 shares of the medical instruments supplier’s stock after selling 7,081 shares during the quarter. Bahl & Gaynor Inc.’s holdings in LeMaitre Vascular were worth $11,264,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC lifted its stake in shares of LeMaitre Vascular by 48.2% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier’s stock valued at $1,227,000 after purchasing an additional 4,330 shares during the period. Townsquare Capital LLC increased its holdings in LeMaitre Vascular by 38.0% during the 3rd quarter. Townsquare Capital LLC now owns 47,953 shares of the medical instruments supplier’s stock worth $4,454,000 after purchasing an additional 13,210 shares in the last quarter. Barclays PLC increased its holdings in LeMaitre Vascular by 394.5% during the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock worth $3,396,000 after purchasing an additional 29,180 shares in the last quarter. Compass Planning Associates Inc bought a new stake in LeMaitre Vascular during the 4th quarter worth approximately $567,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in LeMaitre Vascular by 6.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier’s stock worth $17,789,000 after purchasing an additional 11,395 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Trading Down 1.8 %

Shares of NASDAQ:LMAT opened at $90.47 on Wednesday. The stock’s 50-day moving average price is $96.87 and its 200-day moving average price is $95.00. LeMaitre Vascular, Inc. has a 12-month low of $62.39 and a 12-month high of $109.58. The stock has a market capitalization of $2.03 billion, a P/E ratio of 49.44, a price-to-earnings-growth ratio of 2.22 and a beta of 0.96.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.49. The company had revenue of $55.81 million during the quarter, compared to analyst estimates of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. As a group, research analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th will be issued a $0.20 dividend. The ex-dividend date of this dividend is Thursday, March 13th. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.16. This represents a $0.80 annualized dividend and a yield of 0.88%. LeMaitre Vascular’s dividend payout ratio (DPR) is 41.24%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on LMAT. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Lake Street Capital increased their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Oppenheimer downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Finally, Wells Fargo & Company began coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price objective on the stock. Five analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, LeMaitre Vascular currently has an average rating of “Moderate Buy” and a consensus target price of $95.25.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.